Abstract:Mari Tone 1,2 , Kota Iwahori 1,2 1 Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; 2 Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan Comment on: Rotolo R, Leuci V, Donini C, et al . Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells. Clin Cancer Res 2023;29:621-34. Keywords: Anti programmed death-1 antibody (anti-PD-1 antibody); cancer stemness; non-small cell lung cancer (NSCLC); chemoresistance Submitted Oct 23, 2023. Accepted for publication Jan 05, 2024. Published online Jan 25, 2024. doi: 10.21037/tlcr-23-683 In this editorial commentary, we discussed the potential of programmed death-1 (PD-1) expression on tumor cells as a novel target for the treatment of non-small cell lung cancer (NSCLC) patients based mainly on the findings reported by Rotolo and colleagues (1). We focused on PD-1 expression on tumor cells as a biomarker for combination chemotherapy with anti-PD-1 antibodies and cytotoxic agents as well as future perspectives for PD-1 targeted cancer therapy ( Figure 1 ). Anti-PD-1 blockade is one of the most frequently used immune checkpoint inhibitors in multiple settings, including monotherapy, combination therapy with cytotoxic agents (2), neoadjuvant therapy (3), and post-chemoradiation therapy (4), for patients with NSCLC. While the most common mechanism for the anti-tumor effects of anti-PD-1 blockade is an increase in T cell activity in the tumor microenvironment (5-7), a lymphocyte-independent function was recently reported in melanoma (8-10). Kleffel and colleagues reported that human melanoma tumor tissues frequently contained PD-1-expressing tumor cell subsets. Moreover, an anti-PD-1 antibody inhibited lymphocyte-independent tumor growth in murine models via the mTOR pathway (8). Sanlorenzo and colleagues demonstrated that BRAF and MEK inhibitors increased the number of PD-1-positive melanoma cells, indicating the potential of lymphocyte-independent synergism with anti-PD-1 antibodies (9). In the study that is the focus of this editorial commentary, Rotolo and colleagues reported the novel lymphocyte-independent anti-tumor efficacy of an anti-PD-1 antibody in human and murine NSCLC cell lines (1). The baseline expression of PD-1 in NSCLC cell lines was low and increased after the administration of cisplatin. PD-1 expression was enhanced in stem-like NSCLC pneumospheres, derived from NSCLC cell lines cultured within a defined serum-free medium, exhibiting characteristics reminiscent of stem cells. The anti-PD-1 antibody showed lymphocyte-independent anti-tumor efficacy in vitro and in vivo , and its combination with cisplatin exerted synergistic anti-tumor effects. A question refers to the variance in downstream signaling of PD-1 observed between T cells and tumor cells. Anti-PD1 antibody blocks the growth of PD-1-positive tumor cells, but not PD-1-expressing T cells. Comparison of downstream signaling of PD-1 between T cells and tumor cells will clarify the rational of anti-PD-1 therapy. The study by Rotolo and colleagues focused on the expression of PD-1, not programmed death-ligand 1 (PD-L1), in NSCLC cells. PD-L1 is currently used as a biomarker to predict the efficacy of anti-PD-1 antibody therapy for NSCLC patients (11,12), whereas PD-1 expression has not been reported to be a predictive biomarker of anti-PD-1 treatment outcome in clinical settings. A critical issue for NSCLC patients without driver mutations is that there are currently no useful biomarkers for combination therapy with anti-PD-1 antibodies and cytotoxic agents. PD-L1 expression is not used as a biomarker for the combination therapy with anti-PD-1 antibodies. The findings obtained by Rotolo and colleagues suggested that PD-1-positive NSCLC cells exhibited resistance to cytotoxic chemotherapy. Anti-PD-1 may be used more effectively when NSCLC relapses after the administration of cytotoxic agents for NSCLC highly expressing PD-1. The study by Rotolo and colleagues showed that the concurrent combination of an anti-PD-1 antibody with cisplatin exerted synergistic lymphocyte-independent effects on NSCLC in vivo . The synergistic effects of the combination of anti-PD-1 antibodies with cytotoxic agents have been attributed to immunogenic cell death induced by cytotoxic agents (13). On the other hand, the findings of lymphocyte-independent experiments conducted by Rotolo and colleagues provide a novel viewpoint of anti-PD-1 providing additional efficacy to cytotoxic agents by targeting PD-1-positive NSCLC cells. Therefore, PD-1 expression on NSCLC cells has potential as a predictive biomarker for the efficacy of anti-PD-1 therapy with cytotoxic ag -Abstract Truncated-

The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

The Combination of Anti-Kir Monoclonal Antibodies with Anti-Pd-1/pd-l1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion

PD-L1 blockade enhances anti-tumor efficacy of NK cells

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Investigation of the Mechanism of Action of Anti-Pd-1 Treatment by Systematic Depletion of Different Immune Cell Populations in Syngeneic Models

PD-L1 on Host Cells is Essential for PD-L1 Blockade–mediated Tumor Regression

[Effect of PD-L1 Expression on Activity of NK Killing AML Cell Lines and Its Mechanisms].

Tumor PD-L1 Engages Myeloid PD-1 to Suppress Type I Interferon to Impair Cytotoxic T Lymphocyte Recruitment

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance

Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8+ T Cell Proliferation

Optimization of PD-1 / PD-L1 Blockade to Increase NK Cells Cytotoxicity in Killing Cancer Cells: Article Review”

Tumor Induced PD-L1 on Neutrophils Suppress the Antitumor Immunity of NK Cells Via PD-L1/PD-1 Axis

Cell-intrinsic PD-L1 Ablation Sustains Effector CD8+ T Cell Responses and Promotes Antitumor T Cell Therapy

PD-1-positive Natural Killer Cells Have a Weaker Antitumor Function Than That of PD-1-negative Natural Killer Cells in Lung Cancer

PD-1 expression on tumor cells: a new target for cancer therapy

Intracellular Signaling triggered by engagement of PD-1 by PD-L1

The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines